Pharmalittle: Teva looks for partners; BMS suffers an immunotherapy setback – STAT
|
Pharmalittle: Teva looks for partners; BMS suffers an immunotherapy setback
STAT ood morning, everyone, and welcome to the middle of the week. There’s just a few more days until the rush of meetings and deadlines and paperwork can be put aside for a bit of late-summer relaxation. So, in the meantime, keep plugging away. I’m Rebecca … |
|
Overcoming Resistance to Immunotherapy in Cancer
Specialty Pharmacy Times “There is a great deal of interest in cancer immunotherapy, especially for patients who have metastatic cancer,” said lead researcher Nicholas Restifo, MD. “The response to immunotherapy can be fantastic, but understanding why some patients don’t … |
|
Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer
Xconomy The recent stumbles for cancer immunotherapy—specifically, combinations of treatments meant to help boost its effectiveness—continued late Tuesday with some disappointing news from one of the leaders in the field, Bristol-Myers Squibb. Bristol (NYSE: … |
|
Researchers identify oestrogen receptor stem cells in the mammary gland.
Medical Xpress One of the key questions in stem cell and cancer biology is to understand the cellular hierarchy governing tissue development and maintenance and the cancer cell of origin. In a study published in Cell Reports, researchers lead by Cédric Blanpain, MD … |
|
Monsanto and ToolGen Announce Global Licensing Agreement on CRISPR Platform, Underscore the Benefits of …
Business Wire (press release) “We are excited to bring ToolGen’s CRISPR platform on board at Monsanto, and are continuing to bolster and diversify our capabilities in this field of research,” said Tom Adams, Ph.D., vice president of biotechnology for Monsanto. “As a company we … |